Safety and Pharmacokinetics of Halix(TM) Albuterol Unit Dose Disposable Inhaler Versus Albuterol MDI
An Open-label, Single-Center, Single-Dose, 3-Way Crossover Study of the Safety and Pharmacokinetics of Albuterol Administered by the Halix(TM) Albuterol Unit Dose Disposable Inhaler
Sponsor: Concentrx Pharmaceuticals, Inc.
Listed as NCT03373409, this PHASE1 trial focuses on Asthma and remains completed. Sponsored by Concentrx Pharmaceuticals, Inc., it has been updated 9 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Feb 2019 — Jan 2021 [monthly]
Completed PHASE1
-
Nov 2018 — Feb 2019 [monthly]
Completed PHASE1
▶ Show 4 earlier versions
-
Sep 2018 — Nov 2018 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE1
-
Jan 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Dec 2017 — Jan 2018 [monthly]
Recruiting PHASE1
First recorded
Nov 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Concentrx Pharmaceuticals, Inc.
- Kramer Consulting, LLC
- PharPoint Research, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .